Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | TYK2 | P29597 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NR3C2 | P08235 | 8/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | GSK3B | P49841 | 3/20 | 0.44 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15350159 | 0.86 | LOXL2 (0.54) | TYK2NR3C2TSHRMAPTGSK3B | |
| SCHEMBL91333 | 0.82 | RIOK2 (0.57) | RIOK2PKMTYK2MEN1KMT2A | |
| SCHEMBL2619305 | 0.81 | RIOK2 (0.63) | RIOK2PKMTYK2MEN1KMT2A | |
| SCHEMBL20988697 | 0.79 | RIOK2 (0.54) | RIOK2PKMTYK2MEN1KMT2A | |
| SCHEMBL13180241 | 0.79 | PKM (0.64) | RIOK2PKMMEN1KMT2ANR3C2 | |
| SCHEMBL19699506 | 0.79 | NR3C2 (0.47) | TYK2NR3C2MAPK14MAPTGSK3B | |
| SCHEMBL24598427 | 0.79 | NPC1 (0.51) | RIOK2PKMTYK2TSHRMAPT | |
| SCHEMBL17613356 | 0.79 | TYK2 (0.57) | TYK2TSHRMAPTGSK3BACVRL1 | |
| SCHEMBL19699534 | 0.79 | MAPT (0.59) | RIOK2PKMTYK2MEN1KMT2A | |
| SCHEMBL19728666 | 0.79 | TYK2 (0.53) | RIOK2TYK2MAPTGSK3BACVRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | RIOK2 4834/4885PKM 2979/4885TYK2 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.